

CARD9 RABBIT PAB

货号: S217240

产品全名: CARD9 兔多抗

基因符号: CANDF2; hCARD9

UNIPROT ID: Q9H257 (Gene Accession - BC008877)

背景: The protein encoded by this gene is a member of the CARD protein family, which is defined by the presence of a characteristic caspase-associated recruitment domain (CARD). CARD is a protein interaction domain known to participate in activation or suppression of CARD containing members of the caspase family, and thus plays an important regulatory role in cell apoptosis. This protein was identified by its selective association with the CARD domain of BCL10, a positive regulator of apoptosis and NF-kappaB activation, and is thought to function as a molecular scaffold for the assembly of a BCL10 signaling complex that activates NF-kappaB. Several alternatively spliced transcript variants have been observed, but their full-length nature is not clearly defined.

抗原: Fusion protein of human CARD9

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 1000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Cancer


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human thyroid cancer tissue using 217240(CARD9 Antibody) at a dilution of 1/60(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with the fusion protein and then with 217240(Anti-CARD9 Antibody) at dilution 1/60.



The image on the left is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using 217240(Anti-CARD9 Antibody) at a dilution of 1/60.



In comparison with the IHC on the left, the same paraffin-embedded Human cervical cancer tissue is first treated with fusion protein and then with D222029(Anti-CARD9 Antibody) at dilution 1/60.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
